Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Statistics
Share Statistics
Foghorn Therapeutics has 55.61M shares outstanding. The number of shares has increased by 30.6% in one year.
| Shares Outstanding | 55.61M |
| Shares Change (YoY) | 30.6% |
| Shares Change (QoQ) | 0.48% |
| Owned by Institutions (%) | 63.89% |
| Shares Floating | 27.84M |
| Failed to Deliver (FTD) Shares | 60 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 841.71K, so 1.51% of the outstanding shares have been sold short.
| Short Interest | 841.71K |
| Short % of Shares Out | 1.51% |
| Short % of Float | 3% |
| Short Ratio (days to cover) | 4.04 |
Valuation Ratios
The PE ratio is -2.75 and the forward PE ratio is -3.69. Foghorn Therapeutics's PEG ratio is 0.26.
| PE Ratio | -2.75 |
| Forward PE | -3.69 |
| PS Ratio | 7.93 |
| Forward PS | 4.2 |
| PB Ratio | -3.51 |
| P/FCF Ratio | -2.27 |
| PEG Ratio | 0.26 |
Enterprise Valuation
Foghorn Therapeutics Inc. has an Enterprise Value (EV) of 235.47M.
| EV / Earnings | -2.39 |
| EV / Sales | 6.89 |
| EV / EBITDA | -2.25 |
| EV / EBIT | -2.18 |
| EV / FCF | -1.97 |
Financial Position
The company has a current ratio of 4.11, with a Debt / Equity ratio of -0.58.
| Current Ratio | 4.11 |
| Quick Ratio | 4.11 |
| Debt / Equity | -0.58 |
| Total Debt / Capitalization | -140.34 |
| Cash Flow / Debt | -2.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 1.28% and return on capital (ROIC) is 351.05%.
| Return on Equity (ROE) | 1.28% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | 351.05% |
| Revenue Per Employee | 294.44K |
| Profits Per Employee | -848.5K |
| Employee Count | 116 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4.23M |
| Effective Tax Rate | -0.04 |
Stock Price Statistics
The stock price has increased by -39.42% in the last 52 weeks. The beta is 3.19, so Foghorn Therapeutics's price volatility has been higher than the market average.
| Beta | 3.19 |
| 52-Week Price Change | -39.42% |
| 50-Day Moving Average | 4.79 |
| 200-Day Moving Average | 6.51 |
| Relative Strength Index (RSI) | 46.52 |
| Average Volume (20 Days) | 169.48K |
Income Statement
In the last 12 months, Foghorn Therapeutics had revenue of 34.16M and earned -98.43M in profits. Earnings per share was -2.34.
| Revenue | 34.16M |
| Gross Profit | -75.53M |
| Operating Income | -107.91M |
| Net Income | -98.43M |
| EBITDA | -104.45M |
| EBIT | -107.91M |
| Earnings Per Share (EPS) | -2.34 |
Balance Sheet
The company has 80.34M in cash and 45.07M in debt, giving a net cash position of 35.26M.
| Cash & Cash Equivalents | 80.34M |
| Total Debt | 45.07M |
| Net Cash | 35.26M |
| Retained Earnings | -471.56M |
| Total Assets | 308.37M |
| Working Capital | 214.41M |
Cash Flow
In the last 12 months, operating cash flow was -118.11M and capital expenditures -1.22M, giving a free cash flow of -119.33M.
| Operating Cash Flow | -118.11M |
| Capital Expenditures | -1.22M |
| Free Cash Flow | -119.33M |
| FCF Per Share | -2.84 |
Margins
Gross margin is -221.15%, with operating and profit margins of -315.93% and -288.17%.
| Gross Margin | -221.15% |
| Operating Margin | -315.93% |
| Pretax Margin | -275.8% |
| Profit Margin | -288.17% |
| EBITDA Margin | -305.83% |
| EBIT Margin | -315.93% |
| FCF Margin | -349.38% |
Dividends & Yields
FHTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -48.65% |
| FCF Yield | -44.61% |
Analyst Forecast
The average price target for FHTX is $13, which is 170.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $13 |
| Price Target Difference | 170.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -2.11 |
| Piotroski F-Score | 0 |